IL-6 expression which is a major proinflammatory cytokine18 and an independent prognostic marker for liver steatosis19 was markedly decreased in AFO-202 + N1-63 group (Figure 1E) indicating their application as an anti-fibrotic treatment agent in NASH. Here, IL6 is linked to metabolic dysfunction-associated steatohepatitis.